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of TLR7 (imiquimod) and/or 9 (CpG1826) ligands with DLI
resulted in powerful DLI-mediated GVL reactivity (P0.02),
without clinical signs of GVHD in established C3H.SW3B6
chimeras. The effect was mediated by DLI-derived anti-mHAg-
speciﬁc T cells since adoptive transfer of B6 DLI to the syngeneic
B63B6 chimeras in the presence of TLR ligands did not result in
antitumor immunity. To examine the effects of tissue damage,
established C3H.SW3B6.SJL chimeras were lethally re-irradi-
ated and received C3H.SW BM together with puriﬁed donor
CD8 T cells. Consistent with previous observation, these chime-
ras did not develop severe GVHD despite the fact that skin DCs
were predominantly host-derived. However, if TLR7 ligand was
administered prior to re-irradiation and administration of donor
CD8 T cells, all chimeras developed severe skin and systemic
GVHD (P0.01). To determine whether the donor CD8 T cells
directly recognize host mHAgs and induce tissue damage, we
constructed chimeras using as a host B62m-/- mice in which host
DCs and parenchyma are unable to present MHC class I-restricted
peptides. We found no clinical signs of skin or systemic GVHD in
the re-irradiated C3H.SW3B62m-/- chimeras that received pu-
riﬁed donor CD8 T cells after pre-treatment with TLR7 ligand.
Our data suggest that in MHC-matched setting (1) despite the
presence of host DCs the TLR-mediated signaling is critical for
induction of DLI-mediated GVL reactivity in established chime-
ras; (2) induction of GVHD in established chimeras requires not
only donor T cells, host APCs and TLR ligands, but also tissue
damage. These requirements for GVL reactivity and/or GVHD in
established MHC-matched chimeras clearly differ from those in
freshly irradiated MHC-matched or in established MHC-mis-
matched chimeras.
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SUCCESSFUL THERAPY OF STEROID-REFRACTORY ACUTE GRAFT-VER-
SUS HOST DISEASE WITH SEQUENTIAL ALEMTUZUMAB
Repp, R.1, Claviez, A.2, Schrauder, A.2, Schub, N.1, Gahn, B.1,
Gramatzki, M.1 1Division for Stem Cell Transplantation and Immu-
notherapy, 2nd Medical Department, University of Kiel, Kiel, Germany;
2Department of Pediatrics, University of Kiel, Kiel, Germany.
After allogeneic stem cell transplantation severe acute graft-
versus-host disease (GvHD) is the major limitation of this treat-
ment modality. While in acute GvHD addition of steroids to
immunosuppressive prophylaxis lead to a response rate of 30% to
70%, treatment options of steroid resistant acute GvHD are lim-
ited and no accepted standard for salvage therapy exists. Alemtu-
zumab (Campath-1H) is a commercially available humanized an-
tibody targeting the CD52 antigen, which is expressed on T-cells,
B-cells and on some monocyte derived dendritic cells. For years,
Alemtuzumab has been shown to be effective in GvHD prevention
when used in conditioning regimes, however infectious complica-
tions did limit this approach when routinely applied. In order to
evaluate efﬁcacy and safety of sequential alemtuzumab for severe
acute GvHD, ten patients with steroid-resistant acute GvHD of
grade III or IV involving the gut or/and liver were treated in our
Division. The initial three patients, all with advanced grade IV
GvHD of the liver and already receiving cyclosporine, mycophe-
nolate mofetil and high-dose steroids, were treated with up to 80
mg of alemtuzumab followed by additional 40 mg CD52 antibody
within the next four weeks. While dramatic clinical responses were
seen, such as a bilirubin level of 48 mg/dl returning to normal
within 6 weeks, virus reactivation and bacterial infections were
limiting this approach. Although pronounced lymphocyte deple-
tion seems inevitable for efﬁcacy, additional patients were treated
with lower doses of 20 to 30 mg Alemtuzumab, repeated approx-
imately every two weeks, while concomitant immunosuppressive
drugs could be tapered within 3 to 4 weeks. Acute GvHD improved
in all patients treated so far. A complete response of liver and gut
GvHD was seen in two patients, an additional patient developed a
vanishing bile duct syndrome but has no evidence of ongoing
GvHD. Another two patients are still on treatment with major
improvement of gut and liver-GVHD, respectively. Thus, alemtu-
zumab given sequentially in moderate doses shows promising ac-
tivity in severe, steroid refractory acute GvHD. However, moni-
toring for infectious complications, particularly by reactivated
viruses (CMV, adenovirus) is mandatory for months after treat-
ment.
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IN VIVO BIOLUMINESCENCE AND [18F]-FHBG MICROPET IMAGING
STUDIES OF HUMAN T CELL TRAFFICKING, EXPANSION, AND XENO-
GENEIC GRAFT-VERSUS-HOST-DISEASE FOLLOWING DIFFERENT
ROUTES OF HUMAN T CELL ADMINISTRATION
Rettig, M.P.1, Nervi, B.1, Ritchey, J.K.1, Prior, J.L.1,
Piwnica-Worms, D.1, Wang, H.L.1, Bauer, G.1, Walker, J.1,
Bonyhadi, M.L.2, Berenson, R.J.2, Nolta, J.1, DiPersio, J.F.1 1Wash-
ington University School of Medicine, St. Louis, MO; 2Xcyte Therapies,
Inc., Seattle, WA.
GVHD is the major cause of morbidity and mortality following
allogeneic hematopoietic stem cell transplantation. We previously
demonstrated that 60% of sublethally irradiated NOD/SCID-
2mnull mice develop lethal xenogeneic GVHD (X-GVHD) fol-
lowing retroorbital (r.o.) injection of 107 human T cells (huT).
However, we observed no X-GVHD when the huT were admin-
istered through the lateral tail vein (i.v.). In the current studies, we
used in vivo bioluminescence imaging (BLI) and [18F]FHBG mi-
croPET to evaluate why the route of huT cell administration
affected huT cell engraftment and the development of lethal
XGVHD in NOD/SCID-2mnull mice. We generated huT that
co-expressed chimeric CD34-thymidine kinase (CD34-TK; for
[18F]FHBG microPET) and click beetle red luciferase-egfp
(CBRluc-egfp; for BLI) genes by transducing the cells with two
retroviral vectors, selecting for CD34, and sorting for EGFP
(huTTK/CBR). As before, sub-lethally irradiated NOD/SCID-
2mnull mice injected i.v. with 107 huTTK/CBR failed to develop
lethal XGVHD, whereas 60% of mice injected r.o. developed
lethal XGVHD. Serial whole body BLI and [18F]FHBG micro-
PET revealed very different trafﬁcking patterns and expansion
proﬁles between the i.v. and r.o. routes of huT cell administration.
HuTTK/CBR cells injected i.v. immediately trafﬁcked to the lungs
and failed to expand during the ﬁrst three weeks after infusion. In
contrast, a signiﬁcant portion of the r.o.-injected cells remained in
the retroorbital cavity and trafﬁcked to secondary lymphoid organs
during the ﬁrst 7 days after huTTK/CBR cell infusion. This altered
trafﬁcking of the r.o.-injected cells was associated with a 10-fold
and 5-fold increase in the huTTK/CBR BLI signal and [18F]FHBG
standardized uptake value, respectively, during the ﬁrst 2 weeks
after huT cell infusion, with the huTTK/CBR cells accumulating in
the skin, lymph nodes, lungs and gut. This homing pattern and
strong BLI and [18F]FHBG signals of the r.o.-injected huTTK/CBR
cells remained until death from GVHD. Importantly, histological
examination of the GVHD target tissues revealed changes consis-
tent with human GVHD. Therefore, this NOD/SCID-2mnull
mouse model provides a system to study the pathophysiology of
acute GVHD induced by human cells and aids in the development
of more effective therapies for human GVHD.
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DAY 30 POST-TRANSPLANT ABSOLUTE LYMPHOCYTE AND NATURAL
KILLER CELL COUNT STRONGLY PREDICT OUTCOME AFTER ALLOGE-
NEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIG-
NANCY
Savani, B.N.1, Mielke, S.1, Rezvani, K.1, Yong, A.1, Shenoy, A.1,
Read, E.J.1, Hensel, N.1, Childs, R.1, Barrett, A.J.1 1Hematology
Branch, National Heart Lung and Blood Institute, National Institutes of
Health, Bethesda, MD.
One hundred and ﬁfty-seven patients with leukemia (80 CML,
48 AML, 29 ALL) received a T cell depleted myeloablative allo-
geneic stem cell transplant (SCT) (28 BM and 129 PB) from an
HLA-matched sibling between 09/1993-09/2005. Conditioning
consisted of TBI (12-13.6 Gy)  cyclophosphamide or combined
with ﬂudarabine. T cell dose ranged from 0.2 - 2  105CD3
cells/kg. GVHD prophylaxis was low dose cyclosporine (level 100-
200 ng/ml) in 103 and standard dose in 54. Patients without 
grade II acute GVHD received 1-2 donor lymphocyte infusions
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